Navigation Links
Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals
Date:3/28/2008

TOKYO and WOODCLIFF LAKE, N.J., March 28 /PRNewswire/ -- Eisai Co., Ltd. and its U.S. subsidiary Eisai Inc. (collectively "Eisai") today announced that the United States District Court for the District of New Jersey has ruled in Eisai's favor with respect to Eisai's motion for a preliminary injunction in its patent infringement lawsuit against Teva Pharmaceuticals and its division Gate Pharmaceuticals (collectively "Teva"), concerning Aricept(R) (generic name: donepezil hydrochloride tablets).

As previously announced, Eisai filed the infringement actions in December 2005 contesting Teva's submission of an abbreviated new drug application (ANDA) to the FDA for Aricept(R).

"We are pleased with the court's preliminary injunction decision to prevent the sale of Teva's generic product before the expiration of the donepezil composition of matter patent," said Mr. Hajime Shimizu, Chairman & CEO of Eisai Corporation of North America and Eisai Inc. "We will continue to actively protect our intellectual property throughout the world."

Aricept(R), an acetylcholinesterase inhibitor developed by Eisai Co., Ltd. in Japan, increases the concentration of acetylcholine, a neurotransmitter, in the brain. Aricept(R) was launched in the United States in 1997 and is indicated for the treatment of mild, moderate, and severe dementia of the Alzheimer's type. In the United States, Eisai Inc. copromotes Aricept(R) with Pfizer Inc.

About Eisai Co., Ltd.

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai's corporate human health care (hhc) mission is to give first thought to patients and their families, and to increase the benefits that health care provides. The company believes that increasing patient satisfaction through the development of innovative new medicines exemplifies its important mission. For more information about Eisai Co., Ltd., please visit '/>"/>

SOURCE Eisai Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Eisai/Pfizers Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimers Disease
2. Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application
3. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
4. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
5. Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
6. Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications
7. Kiwa Bio-Tech New Bio-Fertilizer Product Granted Initial Fertilizer Registration Certificate By Ministry of Agriculture of the PRC
8. Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis
9. Odyssey Thera Granted U.S. Patent for Animal Imaging
10. ISTO Technologies Granted Key Patent for Cartilage Cell Expansion by the United States Patent Office
11. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... (PRWEB) June 18, 2013 Demanding industrial ... Lenses engineered of synthetic Sapphire and Glass Ball Lenses, ... from Swiss Jewel Company , of Philadelphia , ... expanding and collimating the light beams without the need ... clarity and natural durability (9 mohs) make it the ...
(Date:6/18/2013)... 2013 RegeneCure announced today ... AMCA Guided Bone Regeneration (GBR) Dental Membrane as a bone ... common problem encountered when patients have a tooth replaced with ... to house the implant. Consequently there is often a need ... natural bone regenerates. The bone substitute material, in turn, needs ...
(Date:6/18/2013)... ALBANY, N.Y. , June 18, 2013 /PRNewswire/ ... that its Burlington, Mass. , ... U.S. Drug Enforcement Administration (DEA) registration to handle ... represents the DEA,s acknowledgement of Burlington,s ... inventory control and documentation. (Logo: ...
(Date:6/18/2013)... Canada (PRWEB) June 18, 2013 ... oversight of pharmaceutical advertising and promotion, and review ... Viewers will learn how to apply these principles ... examples:, ,     The fundamentals on FDA ... and promotional labeling ,     Assessing traditional and ...
Breaking Biology Technology:Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3AMRI Burlington Receives DEA Approval to Handle Controlled Substances 2Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2
... TROMS0, Norway and SEOUL, Korea, June 19 ... KAEL-GemVax,today announced the signing of a collaborative agreement to ... for the treatment of,cancer. , ... CEO Jay,Sangjae Kim, "We are delighted to announce this ...
... research from Cincinnati Children,s Hospital Medical Center highlights the critical ... embryonic development on formation of a normal heart and skull. ... Proceedings of the National Academy of Sciences , a ... the gene/protein SHP2 interferes with the normal developmental activity of ...
... Inc. (OTC Bulletin Board: GOVX), an Atlanta-based biopharmaceutical ... HIV-1 (Human Immunodeficiency Virus), and other infectious agents, announced ... cooperative arrangement with Cook County Board President Todd H. ... County Health and Hospitals Systems Board ("Health System"); and ...
Cached Biology Technology:Lytix Biopharma and KAEL-GemVax Announce Joint Clinical Trial to Combine LTX-315 and GV1001 Cancer Immunotherapy 2Scientists identify gene vital to early embryonic cells forming a normal heart and skull 2GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois 2GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois 3GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois 4GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois 5
(Date:6/18/2013)... chemical modification of DNA and this modification can ... sequence. Until now, scientists believed that this epigenetic ... Today, a team of researchers from the University ... Louis-Jeantet Professor at the Faculty of Medicine, reveals ... that DNA methylation may play both a passive ...
(Date:6/17/2013)... a new virus in patients with severe brain infections ... the virus is responsible for the symptoms of disease. ... 28 out of 644 patients with severe brain infections ... in any of the 122 patients with non-infectious brain ... and central nervous system are often fatal and patients ...
(Date:6/17/2013)... foundations with more modern elements. Using this same approachbut ... Dietrich School of Arts and Sciences have designed a ... storage, and gas transport more efficient and at a ... issue of the Journal of the American Chemical ... builds upon Pitt Associate Professor of Chemistry Nathaniel Rosi,s ...
Breaking Biology News(10 mins):The secret of DNA methylation 2New virus isolated from patients with severe brain infections 2New virus isolated from patients with severe brain infections 3'Chemical architects' build materials with potential applications in drug delivery and gas storage 2
... 12 collaborating institutions have been awarded $24 million in ... for Environmental Implications of Nanotechnology (UC CEIN), which will ... The center, to be housed ... campus, will explore the impact of nanomaterials on life ...
... DURHAM, NC--The National Science Foundation (NSF) and the Environmental ... the Center for Environmental Implications of NanoTechnology (CEINT) to ... Nanoparticles are as much as a million times smaller ... properties compared with larger objects made from the same ...
... University of North Carolina at Chapel Hill School of Medicine ... insulin, the hormone used to treat diabetes. The ... a cure for the millions of people affected by the ... into pluripotent stem cells, or cells that can give rise ...
Cached Biology News:UCLA, partners establish new center on environmental effects of nanotechnology 2UCLA, partners establish new center on environmental effects of nanotechnology 3UCLA, partners establish new center on environmental effects of nanotechnology 4Duke to lead new NSF, EPA center to study the environmental implications of nanotechnology 2Duke to lead new NSF, EPA center to study the environmental implications of nanotechnology 3UNC scientists turn human skin cells into insulin-producing cells 2
... new Vivaspin 2 bridges the gap between ... concentrators. This device combines the speed of ... surface and membrane area for superior recoveries ... a choice of PES, Cellulose Triacetate membranes, ...
... II) is involved in translation initiation. PHAS-II ... proteins bind to eIF-4E, the mRNA cap-binding ... in vitro and in cells. Phosphorylation in ... complexes. This allows eIF-4E to bind to ...
Goat polyclonal to Lipocalin 2...
... Vesicular Monoamine Transporter 2 (VMAT2). An antibody ... a major band at ~55 kDa in ... and not in wild type cells (2). ... molecular weight, were also detected and remain ...
Biology Products: